The Alzheimer’s Disease therapeutic market is projected to grow by $3.9B, accelerating at a CAGR of 8.76% from 2021 to 2026, with 37% of the growth originating in North America, according to a report from Technavio.
One of the major factors driving the expansion of the AD therapies market is the availability, study, and development of novel biomarkers. Another market trends for AD treatments that are promoting the expansion of the therapeutics market for Alzheimer's disease are the emergence of regenerative therapies. However, factors such as the high cost of therapeutics development may threaten the market's growth.